News

Hologic Announces Financial Results for Second Quarter of Fiscal 2022

– Revenue of $1.436 Billion, GAAP Diluted EPS of $1.80, and Non-GAAP Diluted EPS of $2.07 All Significantly Ahead of…

2 years ago

Camber Spine Continues to Add to Its “All Angles” Product Portfolio with Latest Patent Approval

Camber Spine Product Portfolio and Focus Sessions to be Presented at AANS KING OF PRUSSIA, Pa.--(BUSINESS WIRE)--#AANS--Camber Spine, a leading…

2 years ago

Cell MedX Corp. Appoints Mr. Dwayne Yaretz as CEO and Director

Carson City, Nevada--(Newsfile Corp. - April 27, 2022) - Cell MedX Corp. (OTCQB: CMXC) ("Cell MedX" or the "Company"), a…

2 years ago

Corent and IBM Red Hat Achieve Finalist Status for “Best Platform as a Service” in the CODiE Awards

ALISO VIEJO, Calif.--(BUSINESS WIRE)--#CODiE--Corent Technology congratulates the teams at Corent and IBM Red Hat who reached Finalist Status in the…

2 years ago

Cloud DX Signs Clinic in Illinois Strengthening Position in the US

Cloud DX Signs Clinic in Illinois Strengthening Position in the USGrowing its partnership, Cloud DX welcomes the sixth Maxwell clinic…

2 years ago

Jaguar Animal Health Announces Commercial Availability of Plant-based Canalevia-CA1 (Crofelemer) Prescription Drug for the Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs

Canalevia®-CA1 is the first and only treatment for CID in dogs to receive any type of approval from FDASAN FRANCISCO,…

2 years ago

Proxima Clinical Research Honored by Hermes Creative Awards

Proxima CRO recognized with two platinum awards, two gold awards, and five honorable mentions for its creative branding, marketing, and…

2 years ago

Arpa Garay Joins Moderna as Chief Commercial Officer

CAMBRIDGE, MA / ACCESSWIRE / April 27, 2022 / Moderna, Inc., (NASDAQ:MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics…

2 years ago

Jupiter Wellness to Offer Clinical Research Services with Acquisition of Ascent Clinical Research: $3 Million Annual Revenue & EBITDA Contribution to Jupiter

IN A BID TO EXPAND JUPITER WELLNESS'S RESEARCH CAPABILITIES AND ENTER THE LUCRATIVE CRO BUSINESS, JUPITER WELLNESS ACQUIRED THE ASSETS…

2 years ago

Amarantus Signs Non-Binding Term Sheet to Divest Cutanogen Corporation in Exchange for the Extinguishment of Potential $21M+ in Liabilities

Board Member/Acting CEO Provides Shareholder UpdateSale of Engineered Skin Substitute (ESS) subsidiary, Cutanogen Corporation.Emphasis placed on advancing Elto Pharma, Inc.…

2 years ago